Anti-SARS-CoV2 Antibody-mediated Cytokine Release Syndrome in a Patient with Acute Promyelocytic Leukemia

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2022 Jun 12

PMID 35692034

Authors

Ahmed N Hegazy

Jan Kronke

Stefan Angermair

Stefan Schwartz

Carl Weidinger

Ulrich Keller

Sascha Treskatsch

Britta Siegmund

Thomas Schneider

Affiliations

Soon will be listed here.

Abstract

Background: Passive immunization against SARS-CoV-2 limits viral burden and death from COVID-19; however, it poses a theoretical risk of disease exacerbation through antibody-dependent enhancement (ADE). ADE after anti-SARS-CoV2 antibody treatment has not been reported, and therefore the potential risk and promoting factors remain unknown.

Case Presentation: A 75-year-old female was admitted to the emergency room with recurrent, unexplained bruises and leukocytopenia, anemia, and thrombocytopenia. Evaluation of a bone marrow biopsy established the diagnosis of an acute promyelocytic leukemia (APL). SARS-CoV-2 RT-PCR testing of nasal and throat swabs on admission was negative. During the routine SARS-CoV-2 testing of inpatients, our patient tested positive for SARS-CoV-2 on day 14 after admission without typical COVID-19 symptoms. Due to disease- and therapy-related immunosuppression and advanced age conferring a high risk of progressing to severe COVID-19, casirivimab and imdevimab were administered as a preemptive approach. The patient developed immune activation and cytokine release syndrome (CRS) occurring within four hours of preemptive anti-SARS-CoV2 antibody (casirivimab/imdevimab) infusion. Immune activation and CRS were evidenced by a rapid increase in serum cytokines (IL-6, TNFα, IL-8, IL-10), acute respiratory insufficiency, and progressive acute respiratory distress syndrome.

Discussion And Conclusion: The temporal relationship between therapeutic antibody administration and the rapid laboratory, radiological, and clinical deterioration suggests that CRS was an antibody-related adverse event, potentially exacerbated by APL treatment-mediated differentiation of leukemic blasts and promyelocytes. This case highlights the need for careful assessment of life-threatening adverse events after passive SARS-CoV-2 immunization, especially in the clinical context of patients with complex immune and hematological landscapes.

Citing Articles

Non-RBD peptides of SARS-CoV-2 spike protein exhibit immunodominance as they elicit both innate and adaptive immune responses.

Rathore D, Chauhan P, Bonagiri A, Gandhi L, Maisnam D, Kumar R Heliyon. 2024; 10(21):e39941.

PMID: 39568852 PMC: 11577203. DOI: 10.1016/j.heliyon.2024.e39941.

A Review: Understanding Molecular Mechanisms of Antibody-Dependent Enhancement in Viral Infections.

Sawant J, Patil A, Kurle S Vaccines (Basel). 2023; 11(7).

PMID: 37515055 PMC: 10384352. DOI: 10.3390/vaccines11071240.

Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation.

Seow H, Cai J, Pan H, Luo C, Wen K, Situ J J Control Release. 2023; 358:128-141.

PMID: 37084889 PMC: 10148961. DOI: 10.1016/j.jconrel.2023.04.029.

Antibody dependent enhancement-induced hypoxic respiratory failure: A case report.

Elfessi Z, Doyle R, Young L, Knaub M, Yamanaka T Vis J Emerg Med. 2023; 30:101602.

PMID: 36718416 PMC: 9876737. DOI: 10.1016/j.visj.2023.101602.

Theoretical Explanation for the Rarity of Antibody-Dependent Enhancement of Infection (ADE) in COVID-19.

Boldova A, Korobkin J, Nechipurenko Y, Sveshnikova A Int J Mol Sci. 2022; 23(19).

PMID: 36232664 PMC: 9569501. DOI: 10.3390/ijms231911364.

References

Hansen J, Baum A, Pascal K, Russo V, Giordano S, Wloga E . Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020; 369(6506):1010-1014. PMC: 7299284. DOI: 10.1126/science.abd0827. View

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

Taylor P, Adams A, Hufford M, de la Torre I, Winthrop K, Gottlieb R . Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021; 21(6):382-393. PMC: 8054133. DOI: 10.1038/s41577-021-00542-x. View

Lee W, Wheatley A, Kent S, DeKosky B . Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020; 5(10):1185-1191. DOI: 10.1038/s41564-020-00789-5. View

Warrell Jr R, de The H, Wang Z, Degos L . Acute promyelocytic leukemia. N Engl J Med. 1993; 329(3):177-89. DOI: 10.1056/NEJM199307153290307. View

Fajgenbaum D, June C . Cytokine Storm. N Engl J Med. 2020; 383(23):2255-2273. PMC: 7727315. DOI: 10.1056/NEJMra2026131. View

Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W . Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010; 328(5979):745-8. PMC: 3837288. DOI: 10.1126/science.1185181. View

Yamamoto de Almeida L, Pereira-Martins D, Lima A, Baggio M, Koury L, Lange A . Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome. BMC Cancer. 2020; 20(1):821. PMC: 7456372. DOI: 10.1186/s12885-020-07330-1. View

Weinreich D, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R . REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2020; 384(3):238-251. PMC: 7781102. DOI: 10.1056/NEJMoa2035002. View

10.

Schurink B, Roos E, Radonic T, Barbe E, Bouman C, de Boer H . Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe. 2020; 1(7):e290-e299. PMC: 7518879. DOI: 10.1016/S2666-5247(20)30144-0. View

11.

de The H, Chen Z . Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010; 10(11):775-83. DOI: 10.1038/nrc2943. View

12.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507-513. PMC: 7135076. DOI: 10.1016/S0140-6736(20)30211-7. View

13.

Tay M, Poh C, Renia L, Macary P, Ng L . The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020; 20(6):363-374. PMC: 7187672. DOI: 10.1038/s41577-020-0311-8. View

14.

Wang S, Peng Y, Wang R, Jiao S, Wang M, Huang W . Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys. Nat Commun. 2020; 11(1):5752. PMC: 7666115. DOI: 10.1038/s41467-020-19568-1. View

15.

Calandra T, Gerain J, Heumann D, Baumgartner J, Glauser M . High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med. 1991; 91(1):23-9. DOI: 10.1016/0002-9343(91)90069-a. View

16.

Frankel S, Eardley A, Lauwers G, Weiss M, Warrell Jr R . The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med. 1992; 117(4):292-6. DOI: 10.7326/0003-4819-117-4-292. View

17.

Moore J, June C . Cytokine release syndrome in severe COVID-19. Science. 2020; 368(6490):473-474. DOI: 10.1126/science.abb8925. View

18.

Stahl M, Tallman M . Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol. 2019; 187(2):157-162. DOI: 10.1111/bjh.16151. View

19.

Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T . Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. N Engl J Med. 2018; 379(4):327-340. DOI: 10.1056/NEJMoa1800820. View